請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61655完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 翁啟惠 | |
| dc.contributor.author | Tai-Na Wu | en |
| dc.contributor.author | 吳岱娜 | zh_TW |
| dc.date.accessioned | 2021-06-16T13:08:37Z | - |
| dc.date.available | 2018-08-08 | |
| dc.date.copyright | 2013-08-08 | |
| dc.date.issued | 2013 | |
| dc.date.submitted | 2013-08-01 | |
| dc.identifier.citation | 1. Morita M, et al. (1995) Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. Journal of medicinal chemistry 38(12):2176-2187.
2. Natori T, Morita M, Akimoto K, & Koezuka Y (1994) Agelasphins, novel antitumor and immunostimulatory cerebrosides from the marine sponge Agelas mauritianus. Tetrahedron 50(9):2771–2784. 3. Natori T, Koezuka Y, & Higa T (1993) Agelasphins, Novel a-Galactosylceramides from the Marine Sponge Agelas Mauritianus. Tetrahedron Letters 34(35):5591-5592. 4. Joyce S, et al. (1998) Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science 279(5356):1541-1544. 5. Moody DB & Porcelli SA (2003) Intracellular pathways of CD1 antigen presentation. Nature reviews. Immunology 3(1):11-22. 6. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, & Van Kaer L (2004) NKT cells: what's in a name? Nature reviews. Immunology 4(3):231-237. 7. Kronenberg M (2005) Toward an understanding of NKT cell biology: progress and paradoxes. Annual review of immunology 23:877-900. 8. van der Vliet HJ, et al. (2004) The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 112(1):8-23. 9. Taniguchi M, Harada M, Kojo S, Nakayama T, & Wakao H (2003) The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annual review of immunology 21:483-513. 10. Giaccone G, et al. (2002) A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 8(12):3702-3709. 11. Venkataswamy MM & Porcelli SA (2010) Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Seminars in immunology 22(2):68-78. 12. Banchet-Cadeddu A, et al. (2011) The stimulating adventure of KRN 7000. Organic & biomolecular chemistry 9(9):3080-3104. 13. Koch M, et al. (2005) The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol 6(8):819-826. 14. Fujio M, et al. (2006) Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. Journal of the American Chemical Society 128(28):9022-9023. 15. Chang YJ, et al. (2007) Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proceedings of the National Academy of Sciences of the United States of America 104(25):10299-10304. 16. Wu TN, et al. (2011) Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy. Proceedings of the National Academy of Sciences of the United States of America 108(42):17275-17280. 17. Li X, et al. (2010) Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proceedings of the National Academy of Sciences of the United States of America 107(29):13010-13015. 18. Pellicci DG, et al. (2009) Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity 31(1):47-59. 19. Borg NA, et al. (2007) CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448(7149):44-49. 20. Lantz O & Bendelac A (1994) An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. The Journal of experimental medicine 180(3):1097-1106. 21. Dellabona P, Padovan E, Casorati G, Brockhaus M, & Lanzavecchia A (1994) An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. The Journal of experimental medicine 180(3):1171-1176. 22. Makino Y, Kanno R, Ito T, Higashino K, & Taniguchi M (1995) Predominant expression of invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations. International immunology 7(7):1157-1161. 23. Davodeau F, et al. (1997) Close phenotypic and functional similarities between human and murine alphabeta T cells expressing invariant TCR alpha-chains. J Immunol 158(12):5603-5611. 24. Kawano T, et al. (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278(5343):1626-1629. 25. Yoshimoto T & Paul WE (1994) CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. The Journal of experimental medicine 179(4):1285-1295. 26. Arase H, Arase N, Nakagawa K, Good RA, & Onoe K (1993) NK1.1+ CD4+ CD8- thymocytes with specific lymphokine secretion. European journal of immunology 23(1):307-310. 27. Kawakami K, et al. (2003) Critical role of Valpha14+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. European journal of immunology 33(12):3322-3330. 28. Nieuwenhuis EE, et al. (2002) CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nature medicine 8(6):588-593. 29. Tahir SM, et al. (2001) Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 167(7):4046-4050. 30. Dhodapkar MV, et al. (2003) A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. The Journal of experimental medicine 197(12):1667-1676. 31. Bricard G, et al. (2009) Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol 182(8):5140-5151. 32. Liang PH, et al. (2008) Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production. Journal of the American Chemical Society 130(37):12348-12354. 33. Schumann J, Mycko MP, Dellabona P, Casorati G, & MacDonald HR (2006) Cutting edge: influence of the TCR Vbeta domain on the selection of semi-invariant NKT cells by endogenous ligands. J Immunol 176(4):2064-2068. 34. Wei DG, Curran SA, Savage PB, Teyton L, & Bendelac A (2006) Mechanisms imposing the Vbeta bias of Valpha14 natural killer T cells and consequences for microbial glycolipid recognition. The Journal of experimental medicine 203(5):1197-1207. 35. Schumann J, Voyle RB, Wei BY, & MacDonald HR (2003) Cutting edge: influence of the TCR V beta domain on the avidity of CD1d:alpha-galactosylceramide binding by invariant V alpha 14 NKT cells. J Immunol 170(12):5815-5819. 36. Exley M, Garcia J, Balk SP, & Porcelli S (1997) Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. The Journal of experimental medicine 186(1):109-120. 37. McCarthy C, et al. (2007) The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. The Journal of experimental medicine 204(5):1131-1144. 38. Stanic AK, et al. (2003) Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. J Immunol 171(9):4539-4551. 39. Sullivan BA, et al. (2010) Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. J Immunol 184(1):141-153. 40. Schiefner A, Fujio M, Wu D, Wong CH, & Wilson IA (2009) Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands. Journal of molecular biology 394(1):71-82. 41. Park JJ, et al. (2010) Syntheses and biological activities of KRN7000 analogues having aromatic residues in the acyl and backbone chains with varying stereochemistry. Bioorg Med Chem Lett 20(3):814-818. 42. Lin KH, et al. (2010) In vivo protection provided by a synthetic new alpha-galactosyl ceramide analog against bacterial and viral infections in murine models. Antimicrobial agents and chemotherapy 54(10):4129-4136. 43. Berkers CR & Ovaa H (2005) Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol Sci 26(5):252-257. 44. Oki S, Chiba A, Yamamura T, & Miyake S (2004) The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest 113(11):1631-1640. 45. Fujii S, et al. (2006) Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proceedings of the National Academy of Sciences of the United States of America 103(30):11252-11257. 46. Yu KO, et al. (2005) Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proceedings of the National Academy of Sciences of the United States of America 102(9):3383-3388. 47. Uldrich AP, et al. (2011) A semi-invariant V(alpha)10(+) T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen-recognition properties. Nat Immunol 12(7):616-623. 48. Mallevaey T, et al. (2009) T cell receptor CDR2 beta and CDR3 beta loops collaborate functionally to shape the iNKT cell repertoire. Immunity 31(1):60-71. 49. Burdin N, et al. (1998) Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J Immunol 161(7):3271-3281. 50. Wu D, et al. (2005) Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proceedings of the National Academy of Sciences of the United States of America 102(5):1351-1356. 51. Ochsenreither S, et al. (2008) Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations. J Transl Med 6:34. 52. Eberl G & MacDonald HR (2000) Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. European journal of immunology 30(4):985-992. 53. Eberl G, Brawand P, & MacDonald HR (2000) Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation. J Immunol 165(8):4305-4311. 54. Kitamura H, et al. (2000) alpha-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cellular immunology 199(1):37-42. 55. Miyamoto K, Miyake S, & Yamamura T (2001) A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413(6855):531-534. 56. Spada FM, Koezuka Y, & Porcelli SA (1998) CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. The Journal of experimental medicine 188(8):1529-1534. 57. Fan GT, et al. (2005) Synthesis of α-galactosyl ceramide and the related glycolipids for evaluation of their activities on mouse splenocytes. Tetrahedron 61(7):1855–1862. 58. Cui J, et al. (1997) Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278(5343):1623-1626. 59. Yu KO, et al. (2007) Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d. Journal of immunological methods 323(1):11-23. 60. Aspeslagh S, et al. (2011) Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis. The EMBO journal 30(11):2294-2305. 61. Wun KS, et al. (2008) A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR. The Journal of experimental medicine 205(4):939-949. 62. Li X, et al. (2009) Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells. J Immunol 183(7):4415-4421. 63. Dangerfield EM, et al. (2012) Species-specific activity of glycolipid ligands for invariant NKT cells. Chembiochem : a European journal of chemical biology 13(9):1349-1356. 64. Padovan E, Spagnoli GC, Ferrantini M, & Heberer M (2002) IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. Journal of leukocyte biology 71(4):669-676. 65. Takahashi M, et al. (1995) Induction of monocyte chemoattractant protein-1 synthesis in human monocytes during transendothelial migration in vitro. Circulation research 76(5):750-757. 66. Gaudreault E, Fiola S, Olivier M, & Gosselin J (2007) Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. Journal of virology 81(15):8016-8024. 67. Monnier J, et al. (2008) Prokineticin 1 induces CCL4, CXCL1 and CXCL8 in human monocytes but not in macrophages and dendritic cells. European cytokine network 19(4):166-175. 68. Uldrich AP, et al. (2011) A semi-invariant Valpha10+ T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen-recognition properties. Nat Immunol 12(7):616-623. 69. Paget C, Chow MT, Duret H, Mattarollo SR, & Smyth MJ (2012) Role of gammadelta T cells in alpha-galactosylceramide-mediated immunity. J Immunol 188(8):3928-3939. 70. Zhang W, et al. (2011) Introduction of aromatic group on 4'-OH of alpha-GalCer manipulated NKT cell cytokine production. Bioorganic & medicinal chemistry 19(8):2767-2776. 71. Hsieh MH, et al. (2012) Synthesis and evaluation of acyl-chain- and galactose-6'-modified analogues of alpha-GalCer for NKT cell activation. Chembiochem : a European journal of chemical biology 13(11):1689-1697. 72. Oki S, Tomi C, Yamamura T, & Miyake S (2005) Preferential T(h)2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo. International immunology 17(12):1619-1629. 73. Schmieg J, Yang G, Franck RW, & Tsuji M (2003) Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. The Journal of experimental medicine 198(11):1631-1641. 74. Patel O, et al. (2011) NKT TCR recognition of CD1d-alpha-C-galactosylceramide. J Immunol 187(9):4705-4713. 75. Parekh VV, et al. (2004) Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids. J Immunol 173(6):3693-3706. 76. O'Konek JJ, et al. (2011) Mouse and human iNKT cell agonist beta-mannosylceramide reveals a distinct mechanism of tumor immunity. The Journal of clinical investigation 121(2):683-694. 77. Halder RC, Jahng A, Maricic I, & Kumar V (2007) Mini review: immune response to myelin-derived sulfatide and CNS-demyelination. Neurochemical research 32(2):257-262. 78. Zajonc DM, et al. (2005) Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. The Journal of experimental medicine 202(11):1517-1526. 79. Lucia Barbieri, et al. (2004) Immunomodulatory [alpha]-Galactoglycosphingolipids: Synthesis of a 2′-O-Methyl-[alpha]-Gal-GSL and Evaluation of Its Immunostimulating Capacity. European Journal of Organic Chemistry 2004(3):468-473. 80. Lucia Barbieri, et al. (2005) Immunomodulatory [alpha]-Galactoglycosphingolipids: Synthesis of 2'-Fluoro-2'-deoxy-[alpha]-galactosylceramide and an Evaluation of Its Immunostimulating Properties. European Journal of Organic Chemistry 2005(15):3279-3285. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61655 | - |
| dc.description.abstract | Invariant NKT cells (iNKT cells) produce both Th1 and Th2 cytokines in response to α-Galactosylceramide (α-GalCer) stimulation and are thought to be the important effectors in the regulation of both innate and adaptive immunity involved in autoimmune disorders, microbial infections and cancers. However, the anticancer effects of α-GalCer were limited in early clinical trial. In the first study, several analogs of α-GalCer, containing phenyl groups in the lipid tails were found to stimulate murine and human iNKT cells to secrete Th1-skewed cytokines and exhibit greater anticancer efficacy in mice than α-GalCer. We explored the possibility of different Vβ usages of murine Vα14+ iNKT or human Vα24+ iNKT cells, accounting for differential cytokine responses. However, TCR Vβ analysis revealed no significant differences in Vβ usages by α-GalCer and these phenyl glycolipid analogs. On the other hand, these phenyl glycosphingolipids (GSLs) showed greater binding avidity and stability for iNKT TCR when complexed with CD1d. These findings suggest that CD1d-phenyl glycolipid complexes may interact with the same population of iNKT cells but with different avidity and stability to drive Th1 polarization. Thus, this study provides a key to the rational design of Th1 biased CD1d reactive glycolipids in the future.
Further, we replaced their glycan heads with α-Glc or α-Man. Regardless of lipid tail modifications, GSLs with α-Glc head were stronger than those with α-Gal head for humans but weaker for mice in the induction of cytokines/chemokines and expansion/activation of immune cells. The immune-stimulatory potencies were associated with the strength of ternary interaction for each species. It was the iNKT TCR rather than CD1d that dictated the species-specific responses, as demonstrated by mCD1d vs. hCD1d swapping assay. Computer modeling of the ternary complexes provided further insight into the species differences in the TCR structure contributing to the differential binding avidities. In comparison, neither murine nor human iNKT TCR could recognize the GSL with α-Man head. Using Jα18 KO mice, we showed that most cytokines/chemokines induced by GSLs with either α-Glc or α-Gal head were iNKT-dependent. However, there was also iNKT-independent induction of chemokines by the GSL with α-Glc head, which might be mediated by activated monocytes. Thus, our studies showed different effects of the glycan head in mice vs. humans in the ternary interaction and bioactivities, suggesting that immune responses in mice cannot be translated to those in humans. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T13:08:37Z (GMT). No. of bitstreams: 1 ntu-102-F94b46015-1.pdf: 6948320 bytes, checksum: 733a9c45f3e7c804064b24fe25843da0 (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | Contents
Chapter 1. Overview…………………………………………………………………..11 1.1 Background knowledge…………………………………………………………….11 1.2 Research motives…………………………………………………………………...11 1.3 Figures……………………………………………………………………………...14 Chapter 2. Modifications on the lipid tails of glyclipids…………………………….16 2.1 Introduction...............................................................................................................16 2.2 Results……………………………………………………………………………...18 2.2.1 Cytokines induced by phenyl glycolipids in vitro in murine Vα14+ iNKT cells and in vivo………………………………………………………………………………18 2.2.2 Phenyl glycolipid induced cytokines/chemokines production was CD1d-Dependent……………………………………………………………………….20 2.2.3 Anticancer Efficacy of Phenyl Glycolipids…………………………………......21 2.2.4 TCR β chain usage of Vα14+ iNKT Cells upon phenyl glycolipids stimulation……………………………………………………………………………...22 2.2.5 Binding Avidity and stability of mCD1d-Phenyl Glycolipids complex with Vβ8.2+/Vα14+ iNKT Cells………………………………………………………….......22 2.2.6 Cytokine Productions by Human Naive iNKT cells in Response to Phenyl glycolipids……………………………………………………………………………...24 2.2.7 TCR β chain usage of phenyl glycolipids expanded human Vα24+ iNKT cells……………………………………………………………………………………..25 2.2.8 Binding Avidity of hCD1d-Phenyl Glycolipids complex with Vα24+/Vβ11+ iNKT cells……………………………………………………………………………......…....26 2.3 Discussions………………………………………………………………………....27 2.4 Materials and methods………………………………………………………….......31 2.4.1 DN3A4-1.2 Hybridoma cytokine assay……………………………………........31 2.4.2 Determination of murine cytokines/chemokines secretion…………………......32 2.4.3 Binding avidity of various CD1d-loaded glycolipids to Vα14+ iNKT cells…….32 2.4.4 Spectratyping of various glycolipid-expanded Vα24+ iNKT cells……………...33 2.4.5 Glycolipid Analogs of α-GalCer, mice and Cell lines………………………......33 2.4.6 Mouse cancer models…………………………………………………………...34 2.4.7 Binding stability of mCD1d-glycolipid complexes with Vα14+ iNKT cells……35 2.4.8 Isolation and generation of human Vα24+ iNKT cell lines and immature monocyte-derived dendritic cells………………………………………………….........36 2.4.9 Determination of cytokines secretion by human iNKT cells……………………37 2.4.10 FACS analysis of Vβ usages in mice and in humans…………………………..37 2.4.11 Binding avidity of CD1d-loaded glycolipids with Vα24+ iNKT cells…………37 2.5 Figures……………………………………………………………………………...39 2.6 Tables…………………………………………………………………………….....52 Chapter 3. Modifications on the glycan head of glycolipids……………………......56 3.1 Introduction...............................................................................................................56 3.2 Results……………………………………………………………………………...57 3.2.1 The synthesis of glycolipid analogues………………………………………......57 3.2.2 Glycolipid analogs with α-Gal head were stronger immune modulators than those with α-Glc head in mice but weaker in humans………………………………..............58 3.2.3 The binary interaction between mCD1d and glycolipids……………………….61 3.2.4 The ternary interaction between CD1d-GSL complexes and iNKT cells……….63 3.2.5 Effects of swapping human vs. mouse CD1d molecules against human vs. murine iNKT cells on the stimulatory activities of GSLs with different glycan heads…….......64 3.2.6 Structural modeling of the ternary complex of CD1d-GSL-iNKT TCR……......65 3.3 Discussions…………………………………………………………………………68 3.4 Materials and methods………………………………………………………….......74 3.4.1 Characterization of compounds 4-7……………………………………………..74 3.4.2 Injection of glycolipid Analogs of α-GalCer in mice…………………………...76 3.4.3 Determination of murine cytokine/chemokine secretions……………………....76 3.4.4 FACS analyses of mouse immune cells after the specific glycolipid stimulation……………………………………………………………………………...77 3.4.5 Expansion of human iNKT Cells……………………………………………......77 3.4.6 Binding strengths of the binary complex between mCD1d and glycolipid……..78 3.4.7 Binding avidity of various CD1d-loaded glycolipids to Vα14+ iNKT cells…….79 3.4.8 Binding avidity of CD1d-loaded glycolipids with Vα24+ iNKT cells………….79 3.4.9 Isolation and generation of human Vα24+ iNKT cell lines and immature monocyte-derived dendritic cells……………………………………………………….79 3.4.10 mCD1d vs. hCD1d swapping assay…………………………………………...80 3.4.11 Computer modeling and simulation…………………………………………...81 3.5 Figures……………………………………………………………………………...83 Chapter 4. Conclusions and future perspectives………………………………........99 References…………………………………………………………………………….102 Contents (Figures) 1.3.1 Introduction of an aromatic group into the fatty acyl chain of α-GalCer………...14 1.3.2 Structures of α-GalCer analogs and their effects on Th1/Th2 cytokine productions from human NKT cells…………………………………………………………………15 2.5.1 The structure of α-GalCer analogs……………………………………………….40 2.5.2 The capacity of α-GalCer analogs to induce cytokines in murine Vα14+ iNKT hybridoma or mouse serum………………………………………………………….....41 2.5.3 Phenyl glycolipids induced cytokines secretion was CD1d dependent in mice….43 2.5.4 Phenyl glycolipids induced secretions of IL-12p70, MCP-1, and KC were CD1d dependent in mice………………………………………………………………………44 2.5.5 Anticancer efficacy of phenyl glycolipids……………………………………......45 2.5.6 TCR β chain usage of Vα14+ iNKT Cells upon phenyl glycolipids stimulation…47 2.5.7 Binding avidity of murine CD1d-phenyl glycolipid complex with murine iNKT hybridoma cells…………………………………………………………………………48 2.5.8 Binding stability of murine CD1d-glycolipid complexes with murine iNKT cells……………………………………………………………………………………..49 2.5.9 The ability of phenyl glycolipids to stimulate cytokine productions of human naive Vα24+ iNKT cells……………………………………………………………................50 2.5.10 The TCR β chain usage of human Vα24+ iNKT cells expanded by different glycolipids……………………………………………………………………………...51 2.5.11 The interaction between human CD1d-phenyl glycolipids complex with human Vα24+/Vβ11+ iNKT cells……………………………………………………………….53 3.5.1 The structure and synthesis of α-GalCer analogs……………………………...…86 3.5.2 Dose-dependent chemokine secretions triggered by 7DW8-5-Glc…………...….87 3.5.3 Glycolipid analogs with α-Gal head were stronger immune modulators than those with α-Glc head in mice but weaker in humans………………………………………..88 3.5.4 iNKT-dependent productions of cytokines and chemokines…………………......90 3.5.5 FACS analyses of WT mouse immune cells after the indicated glycolipid stimulation……………………………………………………………………………...91 3.5.6 FACS analyses of Jα18 KO mouse immune cells after the indicated glycolipid stimulation……………………………………………………………………………...92 3.5.7 Binding strengths of the binary complex between mCD1d and glycolipid………93 3.5.8 The ternary interaction of CD1d-glycolipid complex with iNKT cells…………..95 3.5.9 CD1d dimer staining of in vivo C1-pulsed splenocytes………………………….97 3.5.10 mCD1d vs. hCD1d swapping assay………………………………………….....98 3.5.11 mCD1d vs. hCD1d swapping assay……………………………………………..99 3.5.12 Computer modeling of the ternary complex of CD1d-GSL-iNKT TCR………100 Contents (Tables) 2.6.1 The spectratyping results of mock-treated Vα24+ iNKT cells……………………54 2.6.2 The spectratyping results of C1-treated Vα24+ iNKT cells…………………...….55 2.6.3 The spectratyping results of C34-treated Vα24+ iNKT cells…………………......56 2.6.4 The spectratyping results of C17-treated Vα24+ iNKT cells…………………......57 | |
| dc.language.iso | en | |
| dc.subject | 結合力 | zh_TW |
| dc.subject | 醣脂質 | zh_TW |
| dc.subject | 抗癌 | zh_TW |
| dc.subject | 自然殺手T細胞 | zh_TW |
| dc.subject | CD1d | zh_TW |
| dc.subject | NKT | en |
| dc.subject | binding avidity | en |
| dc.subject | glycolipid | en |
| dc.subject | CD1d | en |
| dc.subject | anti-cancer | en |
| dc.title | 醣脂質α-GalCer衍生物構造與活性關聯之研究 | zh_TW |
| dc.title | The studies about the structure-activity-relationship (SAR)of glycolipid α-GalCer analogs | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 101-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.coadvisor | 陳鈴津 | |
| dc.contributor.oralexamcommittee | 賴明宗,林國儀,羅傅倫,吳盈達 | |
| dc.subject.keyword | 醣脂質,抗癌,自然殺手T細胞,CD1d,結合力, | zh_TW |
| dc.subject.keyword | glycolipid,anti-cancer,NKT,CD1d,binding avidity, | en |
| dc.relation.page | 108 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2013-08-01 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生化科學研究所 | zh_TW |
| 顯示於系所單位: | 生化科學研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 未授權公開取用 | 6.79 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
